Skip Navigation LinksHome > July 2012 - Volume 20 - Issue 4 > Development of Enteroviral Aseptic Meningitis After Rituxima...
Infectious Diseases in Clinical Practice:
doi: 10.1097/IPC.0b013e3182506ea0
Case Reports

Development of Enteroviral Aseptic Meningitis After Rituximab Treatment of Non-Hodgkin Lymphoma

Givens, Priscilla BS; Velez, Ana Paula MD*; Sandin, Ramon L. MD, MS, FCAP†‡; Quilitz, Rod E. PharmD, BCOP§; Greene, John N. MD, FACP§∥

Collapse Box


Abstract: Rituximab is a monoclonal antibody intended for the treatment of various autoimmune conditions as well as B-cell lymphoid malignancies. It is targeted to the CD20 antigen, which induces apoptosis in mature B cells, making it a useful therapeutic agent against B-cell lymphoid malignancies when used in conjunction with cytotoxic chemotherapy regimens such as cyclophosphamide, hydroxydaunorubicin (doxorubicin), Oncovin (vincristine; Hospira Inc, Lake Forest Ill), and prednisone/prednisolone. It is a very successful treatment of B-cell malignancies but causes profound immunosuppression and elevates the risk of opportunistic infections such as enterovirus meningitis. We report a case of aseptic meningitis in a patient with non-Hodgkin lymphoma after treatment with rituximab in combination with cytotoxic chemotherapy and successful treatment with intravenous immunoglobulin therapy.

© 2012 Lippincott Williams & Wilkins, Inc.

Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.